Nitto-denko Corporation

John Gaudette

Joseph E Payne

Mohammad Ahmadian

Victor Knopov

Richard P Witte

Violetta Akopian

Zheng Hou

Yoshiro Niitsu

Yasunobu Tanaka

Loren A Perelman

Wenbin Ying

Priya Prakash Karmali

Sridhar C Nagarajan

Kwok Yin Tsang

Hao Bai

Bharat Majeti

Jun Zhang

Lei Yu

Seiji Nukui

Roger C Adami

Hai Wang

Haiqing Yin

Neda Safarzadeh

Roger Adami

Elena Feinstein

Igor Mett

Hagar Kalinski

Kenjiro Minomi

Sharon Avkin-Nahum

Yun Liu

Fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, compounds, compositions and methods are to provide nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Fusogenic compounds for delivery of biologically active molecules

Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Ionizable compounds and compositions and uses thereof

This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Lipids for therapeutic agent delivery formulations

Here described is a composition comprising a compound of formula I: wherein Rand Ris independently selected from a group consisting of Cto Calkyl, Cto Calkenyl, and oleoyl group; Rand Rare independently selected from a group consisting of Cto Calkyl, and Cto Calkanol; X is selected from a group consisting of &#x2014;CH&#x2014;, &#x2014;S&#x2014;, and &#x2014;O&#x2014; or absent; Y is selected from &#x2014;(CH), &#x2014;S(CH), &#x2014;O(CH)&#x2014;, thiophene, &#x2014;SO(CH)&#x2014;, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Zis a counterion.

Cationic lipids for therapeutic agent delivery formulations

Here described are compounds consisting of the structure(targeting molecule)-linker-(targeting molecule),wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

Compounds for targeting drug delivery and enhancing siRNA activity

Here described is a method of delivery of a drug to a stellate cell using a composition comprising a compound of formula I: wherein Rand Rare independently selected from Cto Calkyl, Cto Calkenyl, and oleoyl; Rand Rare independently selected from Cto Calkyl and Cto Calkanol; X is selected from &#x2014;CH&#x2014;, &#x2014;S&#x2014;, and &#x2014;O&#x2014;, or X is absent; Y is selected from &#x2014;(CH), &#x2014;S(CH)&#x2014;, &#x2014;O(CH)&#x2014;, -thiophene-, &#x2014;SO(CH)&#x2014;, and ester; n&#x2550;1-4; a&#x2550;1-4; b&#x2550;1-4; c&#x2550;1-4; and Zis a counterion.

What is described is a pharmaceutical composition for treating a fibrotic disease comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.

Retinoid-lipid drug carrier

Here described are compounds consisting of the structure

Here described are compounds of formula I: wherein Rand Rare independently selected from Cto Calkyl, Cto Calkenyl, and oleoyl; Rand Rare independently selected from Cto Calkyl and Cto Calkanol; X is selected from &#x2014;CH&#x2014;, &#x2014;S&#x2014;, and &#x2014;O&#x2014;, or X is absent; Y is selected from &#x2014;(CH), &#x2014;S(CH)&#x2014;, &#x2014;O(CH)&#x2014;, -thiophene-, &#x2014;SO(CH)&#x2014;, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Zis a counterion. Also described herein are compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents, and methods of using these compositions and formulations.

Growing community of inventors

Poway, CA, United States of America

John Gaudette